


Appendix A
FINANCIAL RESULTS AT A GLANCE TO END OCT

Income & Expenditure statement

	Oct-11			Cumulative Apr to Oct 2011		
	Actual £ 000's	Plan £ 000's	Variance £ 000's	Actual £ 000's	Plan £ 000's	Variance £ 000's
Income from all sources	12,598	12,360	238 Fav	85,588	83,304	2,284 Fav
Less : Operating Costs - Pay	7,571	7,037	(534) Adv	51,893	50,988	(905) Adv
- Non Pay	4,223	4,130	(93) Adv	29,337	27,351	(1,986) Adv
EBITDA	804	1,193	(389) Adv	4,358	4,965	(607) Adv
Less : Depreciation	491	456	(35) Adv	3,397	3,403	6 Fav
Operating Reserve/(Deficit)	313	737	(424) Adv	961	1,562	(600) Adv
Less : Financing Costs	271	271	0	1,922	1,916	(6) Adv
Add : Interest Rec'd	2	0	2 Fav	8	6	2 Fav
Current Yr - Surplus/(Deficit)	44	466	(422) Adv	(952)	(348)	(604) Adv



Key cumulative numbers

EBITDA
Operating Surplus
I & E Surplus

Plan £ 000's	Actuals £ 000's	Variance £ 000's
-----------------	--------------------	---------------------

4,965	4,358	(607)
1,562	961	(600)
(348)	(952)	(605)

Margins

EBITDA
Operating Margin


Plan	Actuals	Variance
------	---------	----------

6.0%	5.1%	-0.9%
-0.4%	-1.1%	-0.7%

Bedford Hospital Finance Indicators

October 2011

Finance Indicators



Appendix B

INCOME & EXPENDITURE ANALYSIS TO END OCT

	Annual Plan	Actual to end Oct	Budget to end Oct	CIP variance to end Oct	Other variance to end Oct	Total Variance to end Oct
SLA patient activity	124,737	75,492	72,905		2,587	2,587
SLA Income CIP	1,498	753	1,127	(125)	(249)	(374)
Prov'n Penalties & Contract Adj**	(1,931)	(1,908)	(1,127)		(781)	(781)
Other patient activity	1,728	976	1,008		(32)	(32)
Other operating income	15,389	10,275	9,391	(374)	1,258	884
Total income	141,421	85,588	83,304	(499)	2,783	2,284
Nursing Staff	(27,314)	(16,178)	(15,945)	(158)	(75)	(233)
Medical Staffing	(26,237)	(16,020)	(15,413)	(8)	(599)	(607)
Hca, Support Staffing	(11,268)	(6,351)	(6,590)	(39)	278	239
Scien, Ther, Tech Staffing	(9,208)	(5,577)	(5,387)		(190)	(190)
Admin & Clerical Staffing	(12,264)	(7,215)	(7,179)		(36)	(36)
Management Staffing	(711)	(393)	(417)		24	24
Other Staff Costs	(96)	(159)	(57)		(102)	(102)
Pay CIP (Unidentified 70%)	2,931	0	0		0	0
Total Pay	(84,167)	(51,893)	(50,988)	(205)	(700)	(905)
Clinical Supplies	(18,370)	(11,658)	(11,027)	(221)	(410)	(631)
Hlth Care - Non Nhs Bodies	(7,894)	(5,163)	(4,855)	(63)	(245)	(308)
Hlth Care - Nhs Bodies	(5,850)	(4,117)	(3,411)		(706)	(706)
Premises & Fixed Plant	(5,299)	(3,170)	(3,032)	(2)	(136)	(138)
General Supplies	(1,819)	(1,092)	(1,061)		(32)	(32)
Establishment Exp	(1,659)	(961)	(965)	(49)	53	4
Other Misc Costs	(5,428)	(3,176)	(3,106)		(70)	(70)
Non Pay CIP (Unidentified 30%)	956	0	105	(105)	0	(105)
Reserves	(1,327)	0	0			0
Total non-pay	(46,690)	(29,337)	(27,351)	(440)	(1,546)	(1,986)
Total costs	(130,857)	(81,230)	(78,339)	(645)	(2,246)	(2,891)
EBITDA	10,564	4,358	4,965	(1,144)	537	(607)
Capital Chgs Costs	(5,896)	(3,397)	(3,403)			6
Public Dividend Capital (Pdc)	(2,820)	(1,645)	(1,645)			0
Financing Charges	(465)	(277)	(271)			(6)
Interest Received	11	8	6			2
Total financing costs	(9,170)	(5,310)	(5,313)	0	0	3
Net Surplus/ (deficit)	1,394	(952)	(348)	(1,144)	537	(604)

* the unidentified sum against the CIP target is £3.8m. SHA FIMS profiles will differ due to a different apportionment of the CIP target between Pay and Non Pay

** the provision for penalties identified in the Annual Plan relates to readmissions only

Appendix C

INCOME & ACTIVITY ANALYSIS TO END OCT

Activity	2010-11 Actual activity	2011-12 Activity				2011-12 Plan
		To end of Oct Actual	To end of Oct Plan	To end of Oct Variance	To end of Oct % Variance	
A&E	65,980	39,376	38,004	1,372	4%	63,705
Elective	23,480	14,952	13,445	1,507	11%	23,436
Non elective	21,797	12,100	12,560	(460)	-4%	21,781
Outpatients first and follow ups	238,571	145,130	135,897	9,233	7%	230,547
Outpatient procedures	22,276	13,626	14,099	(473)	-3%	22,793
<i>Total outpatients</i>	260,847	158,756	149,996	8,760	6%	253,340
Chemotherapy	1,921	1,221	1,131	90	8%	1,982
Critical Care	3,136	1,962	1,903	59	3%	3,263

Income	2010-11 Income	2011-12 income				2011-12 Plan
		To end of Oct Actual	To end of Oct Plan	To end of Oct Variance	To end of Oct % Variance	
A&E	5,860	3,825	3,152	673	21%	5,284
Elective	26,449	16,191	14,746	1,446	10%	25,507
Non elective	44,984	25,993	25,446	547	2%	44,061
Outpatients first and follow ups	25,324	14,622	13,936	686	5%	23,665
Outpatient procedures	3,746	2,553	2,664	(112)	-4%	4,312
<i>Total outpatients</i>	29,070	17,175	16,600	574	3%	27,977
Chemotherapy	462	312	265	47	18%	465
Critical Care	4,848	2,848	2,842	7	0%	4,871

PBR income	111,673	66,344	63,050	3,293	5%	108,164
Non-PBR	15,182	9,901	9,514	387	4%	16,573
Total SLA income	126,856	76,245	72,564	3,680	5%	124,737
Total income	126,856	76,245	72,564	3,680	5%	124,737

Unit prices	Planned unit cost	2011-12 Unit price - average				Average per mth (plan)
		Oct Actual	Oct Plan	Oct Variance	% Variance	
A&E	89	97	83	14	17%	82.94
Elective	1,126	1,083	1,097	(14)	-1%	1,088.37
Non elective	2,064	2,148	2,026	122	6%	2,022.89
Outpatients first and follow ups	106	101	103	(2)	-2%	102.65
Outpatient procedures	168	187	189	(2)	-1%	189.17
Chemotherapy	241	255	234	21	9%	234.41
Critical Care	1,546	1,452	1,493	(41)	-3%	1,492.80

Reconciliation Schedules B & C	Income YTD
SLA patient activity - schedule B	75,492
SLA Income CIP - schedule B	753
Equals Total Income YTD - schedule C	76,245

Appendix C3
SUMMARY OF PENALTIES/CONTRACTUAL RISKS & OTHER ADJUSTMENTS TO INCOME

Penalty/Contractual risks	2010-11 Actual	2011-12 Actual										
		Apr - June	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Annual
Readmissions		(484)	(101)	(162)	(220)	(302)						(1,269)
Anticipated readmission challenges						112						112
A&E overperf - casemix		(161)	(164)	(21)	(103)	(111)						(560)
Bal to plan***		(109)	109	0	0	0						0
Contract Queries	(107)	0	0	0	0	0						0
Marginal Rate	(2,150)	(21)	4	(3)	(34)	29						(25)
New to follow ups	(167)	(114)	(33)	(18)	(43)	(60)						(269)
Discharge summaries	(720)	(22)	(15)	(10)	2	(7)						(52)
sub total (provisions)	(3,144)	(910)	(201)	(213)	(398)	(340)	0	0	0	0	0	(2,063)
CQUIN*	(353)	225	(150)	75	75	(150)						75*
Quarter 4 freeze**	233	80	0	0	0	0						80
Sub total (accruals)	(120)	305	(149)	75	75	(150)	0	0	0	0	0	155
Net (provision)	(3,264)	(606)	(351)	(138)	(324)	(490)	0	0	0	0	0	(1,908)

*CQUIN - a positive balance represents the expected achievement to date, not yet invoiced. The Trust has to invoice for 50% prospectively and claim the remainder once achievement is proven. Achievement of 100% for Q1 & Q2 has been confirmed by the PCT and has now been invoiced. The Trust currently expects to achieve 100% for mth 7.

** Quarter 4 freeze - this is the final valuation of the previous year's activity less the estimate already invoiced at year end.

*** Bal to plan represents the assessed risk from overperformance against contracts with issues to be resolved. The Associate PCT plans covered by this provision have been agreed

Appendix D1
SERVICE LINE REPORTS

Surgery

	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
SLA income	25,483	24,847	636	3%
Other income	2,724	2,669	55	2%
Total income	28,207	27,516	691	3%
Total direct costs	-15,433	-13,972	-1,461	-10%
Other Services	-561	-623	62	10%
Theatres	-5,526	-5,330	-196	-4%
Radiology/Pathology	-2,489	-2,489	0	0%
Clin Support Serv	-355	-355	0	0%
Total indirect costs	-8,931	-8,797	-134	-2%
Overheads				
Overhead Costs	-1,414	-1,492	78	5%
Corporate Costs	-2,046	-2,046	0	0%
Total costs	-27,824	-26,307	-1,517	-6%
EBITDA	383	1,209	-826	-68%
Capital charges	-59	-59	0	0%
Net surplus/(deficit)	324	1,150	-826	-72%

Women & Children

	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
SLA income	13,065	13,337	-272	-2%
Other income	609	611	-2	0%
Total income	13,674	13,948	-274	-2%
Total direct costs	-9,163	-8,742	-421	-5%
Other Services	-533	-541	8	1%
Theatres	-590	-684	94	14%
Radiology/Pathology	-1,507	-1,507	0	0%
Clin Support Serv	-244	-244	0	0%
Total indirect costs	-2,874	-2,976	102	3%
Overheads				
Overhead Costs	-1,397	-1,440	43	3%
Corporate Costs	-1,292	-1,292	0	0%
Total costs	-14,726	-14,450	-276	-2%
EBITDA	-1,052	-502	-550	110%
Capital charges	-9	-9	0	0%
Net surplus/(deficit)	-1,061	-511	-550	-108%

Appendix D2
SERVICE LINE REPORTS

Acute Medicine

	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
SLA income	16,587	15,763	824	5%
Other income	753	1,040	-287	-28%
Total income	17,340	16,803	537	3%
Total direct costs	-11,530	-10,860	-670	-6%
Other Services	-2,347	-2,287	-60	-3%
Theatres	0	0	0	0%
Radiology/Pathology	-2,449	-2,449	0	0%
Clin Support Serv	-643	-643	0	0%
Total indirect costs	-5,439	-5,379	-60	-1%
Overheads				
Overhead Costs	-1,412	-1,461	49	3%
Corporate Costs	-1,858	-1,858	0	0%
Total costs	-20,239	-19,558	-681	-3%
EBITDA	-2,899	-2,755	-144	5%
Capital charges	-46	-46	0	0%
Net surplus/(deficit)	-2,945	-2,801	-144	-5%

Specialty Medicine

	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
SLA income	13156	13445	-289	-2%
Other income	321	314	7	2%
Total income	13,477	13,759	-282	-2%
Total direct costs	-7,631	-7,823	192	2%
Other Services	1091	1107	-16	-1%
Theatres	0	0	0	0%
Radiology/Pathology	-1071	-1071	0	0%
Clin Support Serv	-281	-281	0	0%
Total indirect costs	-261	-245	-16	-7%
Overheads				
Overhead Costs	-839	-881	42	5%
Corporate Costs	-598	-598	0	0%
Total costs	-9,329	-9,547	218	2%
EBITDA	4,148	4,212	-64	-2%
Capital charges	-192	-192	0	0%
Net surplus/(deficit)	3,956	4,020	-64	-2%

Appendix D3
SERVICE LINE REPORTS

Clinical Support

	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
SLA income	6,490	6,173	317	5%
Other income	993	638	355	56%
Total income	7,483	6,811	672	10%
Total direct costs	-22,399	-20,572	-1,827	-9%
Other Services	118	118	0	0%
Theatres	6,116	6,014	102	2%
Radiology/Pathology	7,518	7,518	0	0%
Clin Support Serv	1,522	1,516	6	0%
Total indirect costs	15,274	15,166	108	1%
Overheads				
Overhead Costs	-724	-744	20	3%
Corporate Costs	-640	-640	0	0%
Total costs	-8,489	-6,790	-1,699	-25%
EBITDA	-1,006	21	-1,027	-4890%
Capital charges	-997	-997	0	0%
Net surplus/(deficit)	-2,003	-976	-1,027	-105%

Overhead Divisions

	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
Chief Executive	18	6	12	-200%
Dir of OD	107	-11	118	1073%
Dir of Nursing	358	425	-67	16%
COO	73	66	7	-11%
Finance & Corporate	221	-1,716	1,937	
Total	777	-1,230	2,007	

Overall Postion	Actual to date	Budget to date	Variance to date (+ = good, - = bad)	
			£000s	%
Surgery	324	1,150	-826	-72%
Womens & Children	-1,061	-511	-550	108%
Acute Medicine	-2,945	-2,801	-144	5%
Spec Medicine	3,956	4,020	-64	-2%
Clinical Supp Serv	-2,003	-976	-1,027	105%
Chief Executive	18	6	12	-200%
Dir of OD	107	-11	118	1073%
Dir of Nursing	358	425	-67	16%
COO	73	66	7	-11%
Finance & Corporate	221	-1,716	1,937	113%
Net surplus/(deficit)	-952	-348	-604	-174%

Appendix E2
CIP performance - Actual

	2011-12 CIP actual (£000s)							Savings Target	Actual surplus or shortfall vs target	
	Apr	May	Jun	Jul	Aug	Sep	Oct			Total
Acute Medicine										
Acute Med Bed Reconfig								0	45	-45
Remove Recruit & Retention Paym T								0	0	0
Review Non Pay Budgets	5	-5				30	5	35	35	0
Blood Gas Analysier Review	1	1	2	2	1	2	1	10	9	1
Review Of Retirements								0	0	0
Review Of Vacancies		2	2	1	1	1	2	9	13	-4
Early Retiements								0	14	-14
Review of Ward Consumables			9	9	8	8	9	43	43	0
A & E Income (Coding)	40	40	40	40	40	40	60	300	300	0
Outstanding CIP Balance								0	460	-460
								0	0	0
Total Acute Medicine	46	38	53	52	50	81	77	397	918	-522
Specialty Medicine										
Retirements	0	8	8	8	8	8	8	48	48	0
Medical Pay Review - Cardiology	0	0						0	4	-4
Vacancy Review	1	1	2	2	2	2	1	11	10	0
Review Of Non Pay Budgets	1	1	0	0	1	0	1	4	4	0
Specialist Nurse Income	5	5	5	3	5	4	5	32	32	0
Pacemakers Activity	0	75	75	50	49	50	50	349	349	0
								0	0	0
Total Specialty Medicine	7	90	89	63	65	64	65	443	446	-3
Clinical Support CIP										
Theatre Efficiency		6	-5	0	0	0	0	1	22	-21
Procurement Initiatives	2	2	1	1	2	2	2	11	11	0
Review Delivery Options	2	2	1	1	2	2	2	11	11	0
Icu Antibiotics Usage	1	1	1	1	1	1	1	7	7	0
Renegotiate Sevo Contracts	1	1	1	1	1	1	1	7	7	0
Review Rigid Scope Supplier	1	1	0	1	0	0	1	4	4	0
Prosthesis Ctrct Review	0	12	6	6	0	0	0	24	24	0
Review Of Non Pay Budgets	24	24	25	24	24	24	24	169	169	0
Review Of Service Contracts	9	9	9	9	9	9	9	63	63	0
Vacancy Review	9	9	9	9	10	9	9	64	64	0
Thtr Consumables Standardisation					0	0	0	0	100	-100
Review Of Modular Theatre					0	0	0	0	58	-58
Reduce Private Sector Activities					90	30	30	150	150	0
Recruitment & Retention Review					0	0	0	0	25	-25
Pharmacy Purchasing Ctrcts					40	20	20	80	80	0
Phlebotomy Service : Ghh					0	0	0	0	10	-10
Income Generation Activity					0	0	0	0	8	-8
Outstanding CIP Balance					0	0	0	0	453	-453
								0	0	0
Total Clinical Support	49	67	48	53	178	97	98	590	1,266	-676
Surgery										
Renegotiate T&O Kits	4	4	4	3	4	4	4	27	26	0
Review Vascular Rech	2	2	1	1	2	1	2	11	11	0
Productivity Improvements	3	3	3	2	3		0	14	14	0
Dna Reductions	3	3	3	2	3		0	14	14	0
Retirements	2	2	2	3	3	2	0	14	14	0
Prosthesis Ctrct Review	4	4	4	4			0	16	16	0
3rd Party Income	1		2	1	1	1	1	7	7	0
Review Consultant Recharges	1	1	1	3	1	1	2	10	10	0
3rd Party Income	1	-1	0	0	1	2	0	3	5	-2
Bed Review			12	12	11	12	12	59	59	0
Removal Of Vacancies		7	12	10	11	11	12	63	63	0
Retirements		7	2	9	8	9	8	43	43	0
Review Of Budgets		24	12	12	12	12	11	83	83	0
Review of Nursing - 5th Floor			0	0	0	0	0	0	76	-76
Minimise Re-Admissions			0	0	0	25	25	50	175	-125
Prostheis Proc/Standardisation			0	0	0			0	17	-17
Backlog Activity(Nr)			200	100	100	100	100	600	600	0
Outstanding CIP Balance					0			0	317	-317
								0	0	0
Total Surgery	21	56	258	162	160	180	177	1,013	1,549	-536

Appendix E2
CIP performance - Actual

	2011-12 CIP actual (£000s)								Savings Target	Actual surplus or shortfall vs target	
	Apr	May	Jun	Jul	Aug	Sep	Oct	Total			
Womens & Children											
Review Staffing Structures		28	2	11	11	11	27	90	93	-3	
Medical Vacancy O&G		7	3	6	4	4	4	28	28	0	
Staff Red'N (Phase 2 Qipp)		10	5	5	5	5	5	35	35	0	
Drug Cost Review	1	1	1	1	1	1	1	7	7	0	
Nhsia Premium		0	0	0	0	0	0	0	0	0	
Review Antenatal Screening	2	2	1	3	2	2	2	14	14	0	
Gynae Opd Review	1	1	2	0	1	1	1	7	7	0	
Bounty Pack Income	2	2	0	4	2	2	2	14	14	0	
Secretarial Cover Review	1	1	2	0	1	1	1	7	7	0	
Outpatient Staffing Review					0	6	1	7	7	0	
Review Of Np Budgets		2	1	1	1	1	1	7	7	0	
Outstanding CIP Balance		32	11	5	0	0		48	605	-557	
								0	0	0	
Total Womens & Children	7	86	28	36	28	34	45	264	824	-560	
Chief Nurse & Operations											
Clinical Governance Review	2	2	2	2	2	2	2	14	14	0	
Income 3rd Parties			0	0	1	3	0	4	4	0	
Sundry Income	1	1	1	1	1	1	1	7	7	0	
Pay Vacancies/Under Est	7	7	0	4	5	5	4	32	34	-2	
Outstanding CIP Balance					0	10	0	10	21	-11	
Right Sourcing Catering			5	6	6	6	6	29	30	-1	
Accommodation Review				0	0	0	3	3	3	0	
Portering Review				0	0	0	0	0	0	0	
Vending Income	2	-1	2	1	4		2	10	14	-4	
Intro C/Card Facility	2	2	2	2	2		2	12	14	-2	
Restructure Mgmt	1	1	1	1	1		2	7	7	0	
W/End Shop Openings	0	1	1	0	2		2	6	6	0	
Working Arrangements	2	2	2	2	2		4	14	14	0	
Public Parking Chgs	1	1	1	1	1		2	7	7	0	
Review Of Post	1	1	1	1	0	0	0	4	7	-3	
Review Of Storage				0	0	0	0	0	0	0	
Cleaning Materials	1	1	2	2	2	2	2	12	12	0	
Pay Restructure-Mreecs		5	1	3	3	2	2	16	16	0	
Pay Restructure-Cater		5	0	4	0	12	6	27	27	0	
Pay Restructure-Domestics		1	3	5	5	6	5	25	25	0	
Pay Restructure-Residences			3	2	2	2	2	11	11	0	
Pay Review-Add'N Hrs			0	0	0	0	0	0	27	-27	
Service To Car Park			0	0	0	0	0	0	0	0	
Medical Records Uniforms			1	0	0	0	0	1	1	0	
Waste Mgmt Contract			0	0	0	0	0	0	17	-17	
Review Parking Chgs			0	0	0	0	0	0	29	-29	
Catering Income		1	2	2	2	2	2	11	11	0	
Review Staff Parking Chgs			0	0	0	0	0	0	0	0	
Outstanding CIP Balance								0	120	-120	
Total Chief Nurse & Ops	20	30	30	39	41	53	49	262	478	-216	
Clinical Operations											
Removal Of Vacant Posts	0	7	2	3	5	5	5	27	27	0	
Review Of Lean Budget	0	12	6	6	6	6	6	42	42	0	
Review Of Capplan	0	6	5	5	5	5	5	26	31	-5	
Outstanding CIP Balance	0	0	12	2	2	2	2	20	20	0	
									0		
Total Clinical Operations	0	25	25	16	18	18	13	115	120	-5	

Appendix E2
CIP performance - Actual

	2011-12 CIP actual (£000s)								Savings Target	Actual surplus or shortfall vs target
	Apr	May	Jun	Jul	Aug	Sep	Oct	Total		
Finance, Estates, IM&T										
Financing Cost Review	17	-5	0	11	6	6	6	41	41	0
Review Of Rta Income	4	4	4	5	4	4	4	29	29	0
Donated Assets	10	10	10	10	10	10	11	71	71	0
Leasing Review	7	7	7	7	5	7	7	47	47	0
Procurement Initiatives	42	-3	0	100	15	11	28	193	292	-99
Energy Consumption Initiatives	11	11	8	11	11	11	13	76	76	0
Maintenance Staff Review	4	4	4	4	3	4	3	26	26	0
Fire Training Review	0	2	2	1	0	-3	0	2	2	0
Review Of Service Contracts	1	1	1	1	1	1	1	7	7	0
Review Of Minor Improvements	1	1	0	0	1	1	1	4	4	1
Nr - Rates Rebate	0	59	0	0	0	-1	0	59	59	0
Environmental Testing	0	0	1	0	1	0	0	2	2	0
3rd Inc Gsts/Moorfield	6	1	0	-1	4	1	0	11	44	-33
Review On-Call/Overtime			1	1	0	1	0	3	3	0
Review Disater Recovery			1	0	1	0	0	2	2	0
Non Pay Review			0	0	0	0	0	1	1	0
Review Of Mtce Costs	3	-3	0	0	0	0	0	0	18	-18
Reduce Telephone Lease Cost			1	0	0	1	0	2	3	-1
Reduce Ipm Ctrct Costs	3	-3	0	0	0	0	0	0	0	0
Telecoms Restructure			3	3	4	3	4	14	14	0
Nr - Recruitment Freeze	3	3	3	4	4	3	4	24	24	0
Total Fin, Estates, IM&T	112	89	43	157	70	60	82	614	762	-149
HR &OD										
Staffing Structure Review	10	10	10	13	13	13	13	82	82	0
Review It Hardware	1	1	1	1	1	1	1	7	7	0
Consultancy Fees	1	1	0	1	1	0	1	5	5	0
Review Advertising	1	-1	0	0	0	0	0	0	0	0
Nr - Transitional Grant					0	0	0	0	8	-8
Nr - Mgmt Development					0	0	0	0	2	-2
Total HR &OD	13	11	11	15	15	14	15	94	104	-10
Other non attributed										
Insurance Review	1	-1	0	0	0	0	0	0	7	-7
Ft Application Review	5	5	5	5	5	5	5	35	35	0
Total Other	6	4	5	5	5	5	5	35	42	-7
GRAND TOTAL	281	496	590	598	628	606	626	3,825	6,509	-2,684
SHA - CIP Plan Profile									4,559	-734

Appendix G
Capital Expenditure

	2011-12 Capex (£000s)												2012-13	
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Total	C/F
Capex Plan														
Plan submitted 1st Sep 11	201	107	49	90	391	904	602	-159	505	771	651	588	4,700	
													0	
													0	
													0	
Total Capex Plan	201	107	49	90	391	904	602	-159	505	771	651	588	4,700	0
Capex Actual Spend	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Total	C/F
New theatre		3		21	3		10						37	
Building refresh		2	6	68	19	98	165						358	
New theatre - plant						0							0	
IT replacement	150	65	35	0	-8	11	54						307	
Equipment replacement	51	37	2	-3		35	17						159	
Gamma Camera - Plant					430	0							430	
Gamma Camera Build			6	4	7	2	9						28	
													0	
													0	
													0	
Total Capex Actual	201	107	49	90	471	146	255	0	0	0	0	0	1,319	0
Variance	0	0	0	0	-80	758	347	-159	505	771	651	588	3,381	0

Comments

April 2011

Spend to date relates to two items, Healthroster software licences, £138k, and an ultrasound, £56k, both approved last year. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £1,084k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £3,415k not yet approved.

May 2011

Spend to date relates to two items, Healthroster software licences, £138k, Qlikview £56k, a laryngoscope £23k and an ultrasound, £56k. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £1,077k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £3,431k not yet approved.

Jun 2011

Spend to date relates to the Healthroster software licences, £138k, Zircadian Planning Tool, £45k, Qlikview £56k, a laryngoscope £23k and an ultrasound, £56k. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £1,077k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £3,431k not yet approved.

Jul 2011

Spend to date relates to the Healthroster software licences, £138k, Zircadian Planning Tool, £45k, Qlikview £56k, a laryngoscope £23k and an ultrasound, £56k. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £1,195k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £2325k not yet approved.

Aug 2011

Spend to date relates to the Gamma Camera £430k, Healthroster software licences, £138k, Zircadian Planning Tool, £45k, Qlikview £56k, a laryngoscope £23k and an ultrasound, £56k. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £1,374k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £2195k not yet approved.

Sep 2011

Spend to date relates to the Gamma Camera £430k, Healthroster software licences, £138k, Zircadian Planning Tool, £45k, Qlikview £56k, a laryngoscope £23k and an ultrasound, £56k. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £2,039k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £1629k not yet approved.

Oct 2011

Spend to date relates to the Gamma Camera £430k, Healthroster software licences, £138k, Zircadian Planning Tool, £45k, Qlikview £56k, a laryngoscope £23k and an ultrasound, £56k. Committed expenditure, either by way of retentions on previous work or to enable partially completed projects to be completed amounts to a further £1,353k. The Gamma Camera accounts for £660k of this of which £600k will be taken to revenue from the donation from BHC. The CRL is £4,700k leaving £1613k not yet approved.

Appendix H
Cashflow

2011-12 Cashflow (£000s)												
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
Cashflow												
Month end cash balance plan	4,195	3,585	3,637	4,195	4,313	2,415	3,321	4,550	5,592	6,510	7,176	5,353
Revised plan (1)		3,736	3,821	4,492	4,729	3,076	3,994	5,252	5,487	5,916	6,672	5,353
Reassessed			691	1,762	1,999	416	734	1,742	1,727	2,056	4,812	5,353
Revised plan (2)					1,302	10,312	12,952	16,544	19,147	21,657	12,988	5,353
Month end actual cash	1,386	1,730	1,306	940	1,330	9,639	9,699					
Variance	-2,809	-2,006	615	-822	28	-673	-3,253					
	Note 1	Note 2	Note 3	Note 4		Note 5	Note 6					

Note 6

Beds pct and SEPT have significant overdues which Helen is chasing, £2700k and £470k respectively. Also, the FC has agreed extended terms on the debt due from Beds Hospitals Charity, £600k, re the Gamma Camera whilst fund raising events are organised. Payment is following the agreed schedule £200k received to end of Oct

Appendix K

Forecast from M7

	Total	Avg Run rate	M7	Nov	Dec	Jan	Feb	Mar	Total
1 Income to Month 7	85,596	12,228	85,596						85,596
2 Expenditure (incl cap charges) to Month 7	(86,548)	(12,364)	(86,548)						(86,548)
3 Net position as reported	(952)	(136)	(952)						(952)
Add income plan from M8 to Month 12									
4 SLA activity income (based on new overperformance trends to M7)	55,047	11,009		11,211	10,788	10,794	10,529	11,724	55,047
5 less penalties (based on penalties provision to M7)	(1,179)	(236)		(236)	(236)	(236)	(236)	(236)	(1,179)
SHA Funding balance	1,430	286		286	286	286	286	286	1,430
6 Other pt activity income (based on income plan)	720	144		144	144	144	144	144	720
7 Other op income (based on income plan)	6,062	1,212		1,191	1,191	1,190	1,190	1,300	6,062
8 Deduct expenditure plan from M8 to Month 12	(58,647)	(11,729)		(11,868)	(11,574)	(11,611)	(11,497)	(12,097)	(58,647)
9 deduct current overspending estimate	(1,597)	(319)		(323)	(315)	(316)	(313)	(329)	(1,597)
10 Sub total net position next month to year end (incl CIPs)	1,836	367		406	285	252	102	792	1,836
11 Exclude CIPs within plan from M8 to M12 (5 months)	(5,138)	(1,028)		(1,039)	(1,034)	(1,013)	(1,023)	(1,028)	(5,138)
12 Sub total net position between M8 M12 (excluding CIPs)	(3,302)	(660)		(634)	(749)	(761)	(921)	(237)	(3,302)
13 Add back RAG adjusted CIPs from M8 to M12 (5 months)	3,059	612		604	603	609	619	624	3,059
14 Add savings from unidentified CIPs targets from M8 to M12 (5 months)	289	58		57	58	58	58	58	289
15 NHS Bedfordshire (non recurrent claw back)	(600)	(120)						(600)	(600)
16 Other opportunities (eg VAT rebates)	0	0		0					0
17 Significant risk issues (Not dealt with via Reserves - eg GSTS)	(700)	(140)		0	0	0	0	(700)	(700)
18 Additional funding requirement	2,205								
19 Forecast each month	(0)	(111)	(952)	27	(89)	(94)	(244)	(854)	(2,205)
20 Cumulative I&E Position			(952)	(925)	(1,013)	(1,107)	(1,351)	(2,205)	